MAPT and breast carcinoma: The original report linking expression of tau to paclitaxel response in cancer treatment was published by a breast cancer research group; using an unbiased high-throughput approach, the authors identified tau as the most differentially expressed gene associated with a complete response to preoperative paclitaxel-containing chemotherapy [29].